This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 24, 2008
Last updated: November 30, 2010
Last verified: November 2010
The purpose of the study is to examine the effect of AZD5672 (dosed to steady state) on the pharmacokinetics of digoxin (single dose administration).

Condition Intervention Phase
Healthy Volunteers Pharmacokinetics Drug: AZD5672 Drug: Digoxin Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-label Study to Assess the Effect of AZD5672 at Steady State on the Pharmacokinetics of Digoxin Following Single Dose Administration in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • PK variables [ Time Frame: Frequent sampling occasions during study periods ]

Secondary Outcome Measures:
  • Safety variables (adverse events, blood pressure, pulse, safety lab) [ Time Frame: During the whole treatment periods ]

Estimated Enrollment: 24
Study Start Date: July 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AZD5672 + Digoxin (single dose on day 12)
Drug: AZD5672
50 mg, for 13 days
Drug: Digoxin
0.5mg dose
Other Name: Lanoxin
Experimental: 2
AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
Drug: AZD5672
50 mg, for 13 days
Drug: Digoxin
0.5mg dose
Other Name: Lanoxin


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed written informed consent.
  • Females should not be of childbearing potential
  • Clinically normal physical and laboratory findings as judged by the investigator, including negative drug test and negative tests of Hepatitis B surface antigen, antibodies to Hepatitis C virus and antibodies to HIV.

Exclusion Criteria:

  • Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate
  • Known allergy to digoxin or previous complications to digoxin therapy.
  • Participation in any clinical study involving an investigational product in the 3 months prior to enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00723424

Research Site
Berlin, Germany
Sponsors and Collaborators
Study Director: Rod Hepburn AstraZeneca R&D, Charnwood, UK
Principal Investigator: Rainard Fuhr Parexel
  More Information

Responsible Party: Mark Layton, MD, PhD, Medical Science Director, AstraZeneca R&D Alderely Park Identifier: NCT00723424     History of Changes
Other Study ID Numbers: D1710C00021
EudraCt nr 2007-007542-34
Study First Received: July 24, 2008
Last Updated: November 30, 2010

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
CCR5 Receptor Antagonists
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on September 21, 2017